Merus’ Petosemtamab with Pembrolizumab Interim Data Continues to Demonstrate Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
#CloseInOnCancer
ir.merus.nl/news-release...
#CloseInOnCancer
ir.merus.nl/news-release...
May 22, 2025 at 9:32 PM
Merus’ Petosemtamab with Pembrolizumab Interim Data Continues to Demonstrate Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
#CloseInOnCancer
ir.merus.nl/news-release...
#CloseInOnCancer
ir.merus.nl/news-release...
Behind our clinical trials is a group committed to science, strategy, and patient impact. Stefan and the Biomarker Operations team bring passion and precision to advancing Merus’ clinical programs. We’re grateful for their contributions every day.
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
May 28, 2025 at 10:25 AM
Behind our clinical trials is a group committed to science, strategy, and patient impact. Stefan and the Biomarker Operations team bring passion and precision to advancing Merus’ clinical programs. We’re grateful for their contributions every day.
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
We’re thrilled to welcome Brenda, Shelly, and Quimby to our team! Now is an exciting time to be part of Merus. We’re growing, we’re hiring, and we’re making an impact.
Interested in joining us? Explore our opportunities at careers.merus.nl.
#CloseInOnCancer #Hiring #LifeAtMerus #WelcomeToTheTeam
Interested in joining us? Explore our opportunities at careers.merus.nl.
#CloseInOnCancer #Hiring #LifeAtMerus #WelcomeToTheTeam
May 30, 2025 at 10:34 AM
We’re thrilled to welcome Brenda, Shelly, and Quimby to our team! Now is an exciting time to be part of Merus. We’re growing, we’re hiring, and we’re making an impact.
Interested in joining us? Explore our opportunities at careers.merus.nl.
#CloseInOnCancer #Hiring #LifeAtMerus #WelcomeToTheTeam
Interested in joining us? Explore our opportunities at careers.merus.nl.
#CloseInOnCancer #Hiring #LifeAtMerus #WelcomeToTheTeam
Barbara is a member of the Clinical Operations team, where she drives clinical research forward by coordinating trial logistics, leading site management activities, and managing patient recruitment, all while prioritizing patient safety.
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
June 10, 2025 at 10:50 AM
Barbara is a member of the Clinical Operations team, where she drives clinical research forward by coordinating trial logistics, leading site management activities, and managing patient recruitment, all while prioritizing patient safety.
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ 3 distinct mechanisms of action
- Inhibition of EGFR ligand binding and downstream signaling
- Degradation of EGFR via LGR5 internalization
- Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
- Inhibition of EGFR ligand binding and downstream signaling
- Degradation of EGFR via LGR5 internalization
- Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
October 15, 2025 at 10:51 AM
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ 3 distinct mechanisms of action
- Inhibition of EGFR ligand binding and downstream signaling
- Degradation of EGFR via LGR5 internalization
- Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
- Inhibition of EGFR ligand binding and downstream signaling
- Degradation of EGFR via LGR5 internalization
- Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
Warm wishes for the holidays and a bright New Year from all of us at Merus.
#CloseInOnCancer
#CloseInOnCancer
December 9, 2025 at 11:28 AM
Warm wishes for the holidays and a bright New Year from all of us at Merus.
#CloseInOnCancer
#CloseInOnCancer
We’re excited to share this news about our collaboration with Halozyme. Read more about here:
ir.merus.nl/news-release...
#CloseInOnCancer
ir.merus.nl/news-release...
#CloseInOnCancer
November 18, 2025 at 12:15 PM
We’re excited to share this news about our collaboration with Halozyme. Read more about here:
ir.merus.nl/news-release...
#CloseInOnCancer
ir.merus.nl/news-release...
#CloseInOnCancer
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ three distinct mechanisms of action.
Keep following as we highlight each distinct mechanism.
#CloseInOnCancer
Keep following as we highlight each distinct mechanism.
#CloseInOnCancer
September 16, 2025 at 5:24 AM
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ three distinct mechanisms of action.
Keep following as we highlight each distinct mechanism.
#CloseInOnCancer
Keep following as we highlight each distinct mechanism.
#CloseInOnCancer
We’re excited to highlight our grant to the #MakeSenseCampaign, part of the European Head and Neck Society, to help launch a new clinical trials resource on their website. Check it out here:
makesensecampaign.eu/en/cancer-in...
#HNSCC
#CloseInOnCancer
makesensecampaign.eu/en/cancer-in...
#HNSCC
#CloseInOnCancer
December 10, 2025 at 11:13 AM
We’re excited to highlight our grant to the #MakeSenseCampaign, part of the European Head and Neck Society, to help launch a new clinical trials resource on their website. Check it out here:
makesensecampaign.eu/en/cancer-in...
#HNSCC
#CloseInOnCancer
makesensecampaign.eu/en/cancer-in...
#HNSCC
#CloseInOnCancer
We are proud to be developing petosemtamab, with its unique biology designed to have three distinct mechanisms of action: EGFR ligand blocking, EGFR receptor internalization and degradation in LGR5+ cells, and Fc-mediated activation of the innate immune system.
lnkd.in/eyGQrTpF
#CloseInOnCancer
lnkd.in/eyGQrTpF
#CloseInOnCancer
August 26, 2025 at 10:38 AM
We are proud to be developing petosemtamab, with its unique biology designed to have three distinct mechanisms of action: EGFR ligand blocking, EGFR receptor internalization and degradation in LGR5+ cells, and Fc-mediated activation of the innate immune system.
lnkd.in/eyGQrTpF
#CloseInOnCancer
lnkd.in/eyGQrTpF
#CloseInOnCancer
Welcome Bharti, Matthew, and Deitmar! With multiple therapeutic candidates in the clinic, we’re building momentum toward our goal of becoming a leading oncology company. If you’re looking for a place where your work has real meaning, join us
careers.merus.nl
#CloseInOnCancer
careers.merus.nl
#CloseInOnCancer
September 3, 2025 at 10:39 AM
Welcome Bharti, Matthew, and Deitmar! With multiple therapeutic candidates in the clinic, we’re building momentum toward our goal of becoming a leading oncology company. If you’re looking for a place where your work has real meaning, join us
careers.merus.nl
#CloseInOnCancer
careers.merus.nl
#CloseInOnCancer
Today, we honor and thank the global community for helping to advance our clinical programs. Importantly, we are proud of the Merus team who demonstrate unwavering dedication to patients in need of new treatment options.
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
May 20, 2025 at 6:58 PM
Today, we honor and thank the global community for helping to advance our clinical programs. Importantly, we are proud of the Merus team who demonstrate unwavering dedication to patients in need of new treatment options.
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
Today at #Target25, we presented interim clinical data from the phase 2 trial of petosemtamab in combination with standard of care FOLFOX/FOLFIRI in 1L and 2L metastatic colorectal cancer (mCRC) and petosemtamab monotherapy in 3L+ mCRC
#CloseInOnCancer
#ColorectalCancer
ir.merus.nl/news-release...
#CloseInOnCancer
#ColorectalCancer
ir.merus.nl/news-release...
October 24, 2025 at 4:30 PM
Today at #Target25, we presented interim clinical data from the phase 2 trial of petosemtamab in combination with standard of care FOLFOX/FOLFIRI in 1L and 2L metastatic colorectal cancer (mCRC) and petosemtamab monotherapy in 3L+ mCRC
#CloseInOnCancer
#ColorectalCancer
ir.merus.nl/news-release...
#CloseInOnCancer
#ColorectalCancer
ir.merus.nl/news-release...
New talent. Same mission.
When we succeed, we give patients with cancer access to medicines that could change their lives.
We’re excited to welcome our new team members.
If you want to be part of something bigger, now is the time. Join us.
#CloseInOnCancer
When we succeed, we give patients with cancer access to medicines that could change their lives.
We’re excited to welcome our new team members.
If you want to be part of something bigger, now is the time. Join us.
#CloseInOnCancer
October 13, 2025 at 11:26 AM
New talent. Same mission.
When we succeed, we give patients with cancer access to medicines that could change their lives.
We’re excited to welcome our new team members.
If you want to be part of something bigger, now is the time. Join us.
#CloseInOnCancer
When we succeed, we give patients with cancer access to medicines that could change their lives.
We’re excited to welcome our new team members.
If you want to be part of something bigger, now is the time. Join us.
#CloseInOnCancer
Petosemtamab is a novel and highly innovative bispecific antibody in development for Head and Neck cancer and Colorectal cancer, with a unique mechanism of action. www.mdpi.com/2072-6694/17...
Stay tuned to learn more about petosemtamab’s unique mechanism of action.
#CloseInOnCancer #HNSCC #CRC
Stay tuned to learn more about petosemtamab’s unique mechanism of action.
#CloseInOnCancer #HNSCC #CRC
September 10, 2025 at 5:36 AM
Petosemtamab is a novel and highly innovative bispecific antibody in development for Head and Neck cancer and Colorectal cancer, with a unique mechanism of action. www.mdpi.com/2072-6694/17...
Stay tuned to learn more about petosemtamab’s unique mechanism of action.
#CloseInOnCancer #HNSCC #CRC
Stay tuned to learn more about petosemtamab’s unique mechanism of action.
#CloseInOnCancer #HNSCC #CRC
This season, we’re thankful for our colleagues, collaborators, and the patients and families impacted by cancer, who inspire our work every day.
Happy Thanksgiving from all of us at Merus.
#CloseInOnCancer
Happy Thanksgiving from all of us at Merus.
#CloseInOnCancer
November 26, 2025 at 11:24 AM
This season, we’re thankful for our colleagues, collaborators, and the patients and families impacted by cancer, who inspire our work every day.
Happy Thanksgiving from all of us at Merus.
#CloseInOnCancer
Happy Thanksgiving from all of us at Merus.
#CloseInOnCancer
Interim data on petosemtamab presented today at #Targets25 demonstrate a robust response rate and a favorable, well-tolerated safety profile in metastatic colorectal cancer.
merus.nl/wp-content/u...
#CloseInOnCancer
#ColorectalCancer
merus.nl/wp-content/u...
#CloseInOnCancer
#ColorectalCancer
October 24, 2025 at 2:02 PM
Interim data on petosemtamab presented today at #Targets25 demonstrate a robust response rate and a favorable, well-tolerated safety profile in metastatic colorectal cancer.
merus.nl/wp-content/u...
#CloseInOnCancer
#ColorectalCancer
merus.nl/wp-content/u...
#CloseInOnCancer
#ColorectalCancer
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ 3 distinct mechanisms of action:
-Inhibition of EGFR ligand binding and downstream signaling
-Degradation of EGFR via LGR5 internalization
-Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
-Inhibition of EGFR ligand binding and downstream signaling
-Degradation of EGFR via LGR5 internalization
-Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
October 21, 2025 at 10:53 AM
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ 3 distinct mechanisms of action:
-Inhibition of EGFR ligand binding and downstream signaling
-Degradation of EGFR via LGR5 internalization
-Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
-Inhibition of EGFR ligand binding and downstream signaling
-Degradation of EGFR via LGR5 internalization
-Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
On #WorldCancerResearchDay, we stand united with researchers around the world working towards new treatments and improved outcomes for patients living with cancer.
#CloseInOnCancer
#CloseInOnCancer
September 24, 2025 at 4:53 AM
On #WorldCancerResearchDay, we stand united with researchers around the world working towards new treatments and improved outcomes for patients living with cancer.
#CloseInOnCancer
#CloseInOnCancer
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ three distinct MOAs:
- Inhibition of EGFR ligand binding and downstream signaling
- Degradation of EGFR via LGR5 internalization
- Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
- Inhibition of EGFR ligand binding and downstream signaling
- Degradation of EGFR via LGR5 internalization
- Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
September 22, 2025 at 10:15 AM
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ three distinct MOAs:
- Inhibition of EGFR ligand binding and downstream signaling
- Degradation of EGFR via LGR5 internalization
- Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
- Inhibition of EGFR ligand binding and downstream signaling
- Degradation of EGFR via LGR5 internalization
- Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
Innovation drives progress – and meaningful progress comes when new therapies are both efficacious and safe. On #WorldPatientSafetyDay, and every day, we reaffirm our commitment to making patient safety a cornerstone in the development of new potential treatments for cancer.
#CloseInOnCancer
#CloseInOnCancer
September 17, 2025 at 4:12 AM
Innovation drives progress – and meaningful progress comes when new therapies are both efficacious and safe. On #WorldPatientSafetyDay, and every day, we reaffirm our commitment to making patient safety a cornerstone in the development of new potential treatments for cancer.
#CloseInOnCancer
#CloseInOnCancer
We’re thrilled to welcome new members to the Merus team! Their expertise and passion will help us advance our novel approach to fighting cancer.
Now is an exciting time to be part of Merus.
Interested in joining us? Explore our opportunities.
#CloseInOnCancer
Now is an exciting time to be part of Merus.
Interested in joining us? Explore our opportunities.
#CloseInOnCancer
August 7, 2025 at 5:31 PM
We’re thrilled to welcome new members to the Merus team! Their expertise and passion will help us advance our novel approach to fighting cancer.
Now is an exciting time to be part of Merus.
Interested in joining us? Explore our opportunities.
#CloseInOnCancer
Now is an exciting time to be part of Merus.
Interested in joining us? Explore our opportunities.
#CloseInOnCancer
When the lab coats come off and the computers shut down, the thinking caps stay on. Meet the Merus Pub Quiz crew, a highly competitive group of colleagues participating in local trivia nights. It's just one of the ways we stay connected – and sharp – when we’re off the clock.
#CloseInOnCancer
#CloseInOnCancer
August 5, 2025 at 10:39 AM
When the lab coats come off and the computers shut down, the thinking caps stay on. Meet the Merus Pub Quiz crew, a highly competitive group of colleagues participating in local trivia nights. It's just one of the ways we stay connected – and sharp – when we’re off the clock.
#CloseInOnCancer
#CloseInOnCancer
Merus will hold a conference call and webcast on Thursday, May 22nd, at 5:30 p.m. ET to discuss updated interim clinical data on petosemtamab with pembrolizumab in 1L PD-L1+ r/m #HNSCC. The presentation and replay will be available in the Investors & Media section of our website.
#CloseInOnCancer
#CloseInOnCancer
May 22, 2025 at 11:58 AM
Merus will hold a conference call and webcast on Thursday, May 22nd, at 5:30 p.m. ET to discuss updated interim clinical data on petosemtamab with pembrolizumab in 1L PD-L1+ r/m #HNSCC. The presentation and replay will be available in the Investors & Media section of our website.
#CloseInOnCancer
#CloseInOnCancer
Yesterday, we celebrated Clinical Trial Awareness Day.
In the coming days, we’ll introduce you to Merus team members who embody our company-wide passion and sense of urgency to bring new treatments to patients with cancer.
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
In the coming days, we’ll introduce you to Merus team members who embody our company-wide passion and sense of urgency to bring new treatments to patients with cancer.
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
May 21, 2025 at 10:54 AM
Yesterday, we celebrated Clinical Trial Awareness Day.
In the coming days, we’ll introduce you to Merus team members who embody our company-wide passion and sense of urgency to bring new treatments to patients with cancer.
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
In the coming days, we’ll introduce you to Merus team members who embody our company-wide passion and sense of urgency to bring new treatments to patients with cancer.
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer